Kytopen Corp., a Cambridge, Mass.-based biotechnology company spun out of MIT offering a scalable technology for engineered cell therapies, raised $30m in Series A funding.
The round was led by Northpond Ventures, with participation from current investors The Engine, Horizon Ventures, and Mass Ventures, as well as Aldevron Co-Founders Michael Chambers and John Ballantyne and Alexandria Venture Investments. Adam Wieschhaus, Ph.D., CFA, Director at Northpond Ventures, will join the Kytopen board of directors along with Kytopen Co-Founders Paulo Garcia and Cullen Buie and Theresa Tribble, Venture Partner at The Engine.
The company intends to use new capital to commercialize its Flowfect® Tx for cGMP-compliant cell therapy manufacturing and move towards treating the first human patient with Flowfect® engineered cells.
Led by Paulo Garcia, Ph.D., CEO and Co-Founder, Kytopenis advancing the Flowfect® platform, which eliminates the complexity of gene editing and integrates discovery, development, and manufacturing in one flexible and scalable non-viral delivery solution.
The Flowfect® technology utilizes electro-mechanical energy to introduce genetic material such as RNA, DNA, or CRISPR/Cas RNP, to a wide variety of hard-to-transfect primary human cells. The technology enables cell engineering in minutes for target discovery and process development optimization.